Clinical trial
The Effectiveness of Alemtuzumab Combination With CHOP to Treat Patients Newly…
NCT00441025 · Mahidol University, Other · Terminated
Key facts
| NCT number | NCT00441025 |
|---|---|
| Title | The Effectiveness of Alemtuzumab Combination With CHOP to Treat Patients Newly Diagnosed With PTCL |
| Official title | A Phase II Study of Alemtuzumab in Combination With CHOP as First-Line Treatment in Peripheral T-Cell Lymphoma |
| Lead sponsor | Mahidol University, Other |
| Collaborators | Bayer Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Peripheral T-Cell Lymphoma |
| Intervention type | Drug |
| Interventions | Alemtuzumab |
| Enrollment | 4 |
| Start date | Sep 1, 2006 |
| Completion | Aug 1, 2009 |
| First posted | Feb 27, 2007 |
| Last update posted | Jun 25, 2009 |
| Countries | Thailand |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: